Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 109913618 | 10991361 | 8 | F | 20150303 | 20160824 | 20150406 | 20160901 | EXP | US-PFIZER INC-2015115764 | PFIZER | 72.00 | YR | M | Y | 99.00000 | KG | 20160901 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 109913618 | 10991361 | 1 | SS | NAPROXEN. | NAPROXEN | 1 | Oral | UNK | 0 | TABLET | |||||||||
| 109913618 | 10991361 | 2 | SS | NAPROXEN. | NAPROXEN | 1 | 0 | TABLET | |||||||||||
| 109913618 | 10991361 | 3 | PS | LYRICA | PREGABALIN | 1 | Oral | 100 MG, 3X/DAY | Y | 21446 | 100 | MG | TID | ||||||
| 109913618 | 10991361 | 4 | SS | TRAZODONE | TRAZODONE HYDROCHLORIDE | 1 | Oral | UNK | Y | 0 | |||||||||
| 109913618 | 10991361 | 5 | SS | TRAMADOL. | TRAMADOL | 1 | Oral | 50 MG, 3X/DAY | 68100 | MG | Y | 0 | 50 | MG | TID | ||||
| 109913618 | 10991361 | 6 | SS | HYDROCODONE | HYDROCODONE | 1 | Oral | UNK | Y | 0 | |||||||||
| 109913618 | 10991361 | 7 | C | SIMVASTATIN. | SIMVASTATIN | 1 | Oral | 40 MG, QD | 0 | 40 | MG | QD | |||||||
| 109913618 | 10991361 | 8 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | Oral | 500 MG,BID | 0 | 500 | MG | BID | |||||||
| 109913618 | 10991361 | 9 | C | MORPHINE pump | MORPHINE | 1 | Intramuscular | 0.45 MG, PRN | 0 | .45 | MG | ||||||||
| 109913618 | 10991361 | 10 | C | CYMBALTA | DULOXETINE HYDROCHLORIDE | 1 | Oral | 40 MG, QD | 0 | 40 | MG | QD | |||||||
| 109913618 | 10991361 | 11 | C | VESICARE | SOLIFENACIN SUCCINATE | 1 | Oral | 5 MG, QD | 0 | 5 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 109913618 | 10991361 | 1 | Osteoarthritis |
| 109913618 | 10991361 | 2 | Rheumatoid arthritis |
| 109913618 | 10991361 | 3 | Neuropathy peripheral |
| 109913618 | 10991361 | 4 | Pain |
| 109913618 | 10991361 | 5 | Osteoarthritis |
| 109913618 | 10991361 | 6 | Pain |
| 109913618 | 10991361 | 7 | Dyslipidaemia |
| 109913618 | 10991361 | 8 | Insulin resistance |
| 109913618 | 10991361 | 9 | Back pain |
| 109913618 | 10991361 | 10 | Anxiety |
| 109913618 | 10991361 | 11 | Hypertonic bladder |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 109913618 | 10991361 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 109913618 | 10991361 | Mental status changes |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 109913618 | 10991361 | 1 | 20120906 | 20130328 | 0 | |
| 109913618 | 10991361 | 3 | 2009 | 20150304 | 0 | |
| 109913618 | 10991361 | 4 | 20150225 | 20150303 | 0 | |
| 109913618 | 10991361 | 5 | 20131205 | 20150304 | 0 | |
| 109913618 | 10991361 | 6 | 20150225 | 20150303 | 0 | |
| 109913618 | 10991361 | 7 | 201412 | 0 | ||
| 109913618 | 10991361 | 8 | 2009 | 0 | ||
| 109913618 | 10991361 | 9 | 20110902 | 0 | ||
| 109913618 | 10991361 | 10 | 20140616 | 0 | ||
| 109913618 | 10991361 | 11 | 20140510 | 0 |